Clinically-validated
Macrophage
Technology Platform
Halts ALS Progression
Regulates Multiple Immune Factors
Primed for FDA Approval
We’re a Multifactorial
Immune Regulator Platform
Efficacy
Our drug (NP001) shows immediate responsiveness in patient population with no effective treatment available.
Safety Profile
No drug-related SAEs (3 clinical trials), with robust safety profile
Regulatory
Orphan drug and Fast Track assigned designation; seek accelerated approval for ALS patients.
Strong IP
8 issued patents US and ROW (through 2042)
Sales
Well-defined ALS clinics enable sales by small sales force.
Market
$3 billion in US and Europe